PCG
AVIR icon

Private Capital Group’s Atea Pharmaceuticals AVIR Stock Holding History

Private Capital Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1K Buy
+156
New +$1.06K ﹤0.01% 1663

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Private Capital Group's AVIR Position: Q2 2022 in Review

Private Capital Group opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2022: 156 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1663 among its holdings.

127 funds tracked by Wall St. Rank hold AVIR as of Q2 2022.

  • Private Capital Group held 156 shares of Atea Pharmaceuticals worth $1K as of Q2 2022.
  • Atea Pharmaceuticals was a new Private Capital Group position in Q2 2022.
  • Atea Pharmaceuticals made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1663 holding.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.